Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
622
Shown on this page
12
Current sort
Recently updated
Campus scope
Beth Israel Deaconess Medical Center, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Beth Israel Deaconess Medical Center, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 505–516 of 622 matching trials with a site at Beth Israel Deaconess Medical Center, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial

NCT06895590
Status at this site: Recruiting
View directory record Official record
Conditions
Non-cardiac Surgical, Intensive Care Unit (ICU)
Interventions
Philips Advanced Monitoring Cuff (i.e. AMC)
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Active, not recruiting Phase 1 Interventional

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

NCT03974217
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia
Interventions
Talazoparib, Decitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Recruiting Phase 3 Interventional

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

NCT02933489
Site status not listed — check the official record
View directory record Official record
Conditions
Asymptomatic
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration
Diagnostic Test · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
40 Years to 75 Years · Female only
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
67
States / cities
Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

NCT02716116
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
TAK-788
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Recruiting Not applicable Interventional

The Impact of Dry Needling on Electrophysiological and Ultrasound-based Biomarkers for Myofascial Pain

NCT07270276
Status at this site: Recruiting
View directory record Official record
Conditions
Trigger Point in Trapezius Muscle
Interventions
Dry Needling, Sham Treatment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

NCT00378105
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

NCT01366092
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Recruiting Phase 2 Interventional

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

NCT06854003
Status at this site: Recruiting
View directory record Official record
Conditions
Mantle Cell Lymphoma, Lymphoma
Interventions
Bendamustine, Rituximab, Cytarabine, Zanubrutinib, Sonrotoclax
Drug
Lead sponsor
Christine Ryan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
7
States / cities
Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

NCT02677922
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AG-120, Azacitidine, AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Recruiting Not applicable Interventional

Mind Body Intervention for Long COVID-19

NCT06045338
Status at this site: Recruiting
View directory record Official record
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 27, 2026, 8:20 PM EDT
Recruiting Not applicable Interventional

Mind Body Intervention for Chronic Upper Extremity Pain (Repetitive Stress Injury)

NCT06903962
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Repetitive Stress Injury
Interventions
Mind-Body Intervention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 27, 2026, 8:20 PM EDT

About this Beth Israel Deaconess Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.